We recently compiled a list of the 10 Best Immunotherapy Stocks to Buy Now. In this article, we are going to take a look at ...
This was partly offset by a 1% rise in the company’s revenue from $46 billion to $47 billion over the same period; and a 4.1% ...
Bristol Myers Squibb (NYSE: BMY) recently reported its Q3 results, with revenues and earnings exceeding the street estimates.
Daiwa America upgraded shares of Bristol-Myers Squibb (NYSE:BMY – Free Report) from a hold rating to a strong-buy rating in a ...
1d
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Bristol-Myers Squibb (BMY – Research Report) ...
Hosted on MSN6d
What's Behind the Insider Buying on This High-Yield Stock?In the company’s first insider transaction in nearly a year, Hirawat bought approximately $100,000 worth of BMY stock on Nov.
Leerink upgrades Bristol-Myers Squibb with an increased price target and strong sales projections for Cobenfy and milvexian, ...
On Friday, Bristol-Myers Squibb Co (BMY) stock saw a decline, ending the day at $54.14 which represents a decrease of $-0.57 or -1.04% from the prior close of $54.71. The stock opened at $54.7 and ...
BRISTOL-MYERS SQUIBB CO (BMY) is a large-cap stock in the Biotechnology & Drugs industry. The rating using this strategy is 88% based on the firm’s underlying fundamentals and the stock’s ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback